Takeda Expands Real-World Evidence for Takhzyro With New Saudi Arabia HAE Study
Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Takeda’s new REFLEQT-KSA study, officially titled “Retrospective Chart Review Study Evaluating Clinical Effectiveness and Impact on Quality of Life Among Patients Who Initiated Long-term Prophylaxis With Takhzyro in a Real-World Setting in the Kingdom of Saudi Arabia,” will track how well Takhzyro (lanadelumab) controls hereditary angioedema in daily practice. The focus is on real-world attack reduction and quality of life in teenagers and adults in Saudi Arabia, a key growth region for rare disease care.
The study reviews patients with hereditary angioedema types 1 and 2 who already receive Takhzyro as long-term preventive therapy. Takhzyro is an injected treatment designed to cut the number and severity of swelling attacks over time.
This is an observational, retrospective cohort study that does not assign or change treatment. Researchers will review existing medical records before and after Takhzyro start, with no placebo or blinding, to see how outcomes shift once patients are on steady prevention.
The index period for chart data runs from 01 Sep 2025 to 28 Feb 2026, capturing at least 6 months of treatment data per patient where possible. The record was last updated on 23 Feb 2026, signaling that planning is active, but recruitment has not yet started and timelines may still move.
For investors, this update supports Takeda’s push to strengthen Takhzyro’s real-world evidence base, which can help defend pricing and support uptake in the Middle East. Strong results could reinforce its moat in hereditary angioedema against current and future rivals, while weaker data could open the door for competing prophylactic options and weigh on sentiment.
The REFLEQT-KSA study is not yet recruiting but remains an active, updated project, with further details available on the ClinicalTrials portal.
To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.
